Baxter has published its financial report for 2011, hailing the year as a "very successful" period for the company.
The firm's worldwide sales advanced by eight percent year on year during the 12 months to $13.89 billion (8.84 billion pounds), allowing the company to make record levels of investment in research and development.
Recent business highlights include the initiation of new trials for products such as Kiovig, BAX 855 and a new home haemodialysis device, as well as the agreement of new collaborations and the completion of its Baxa Corporation takeover.
For the 2012 full-year period, the company now expects to achieve a sales increase of between four and five percent, with two percent growth forecast for the first quarter.
Robert Parkinson Jr, chairman and chief executive officer of Baxter, said: "2011 was a very successful year for Baxter as we continue to fulfil our mission of providing innovative life-saving and life-sustaining therapies that advance patient care worldwide."
This comes after the firm appointed Jean-Luc Butel as its new corporate vice-president and president of international operations earlier this month.
The firm's worldwide sales advanced by eight percent year on year during the 12 months to $13.89 billion (8.84 billion pounds), allowing the company to make record levels of investment in research and development.
Recent business highlights include the initiation of new trials for products such as Kiovig, BAX 855 and a new home haemodialysis device, as well as the agreement of new collaborations and the completion of its Baxa Corporation takeover.
For the 2012 full-year period, the company now expects to achieve a sales increase of between four and five percent, with two percent growth forecast for the first quarter.
Robert Parkinson Jr, chairman and chief executive officer of Baxter, said: "2011 was a very successful year for Baxter as we continue to fulfil our mission of providing innovative life-saving and life-sustaining therapies that advance patient care worldwide."
This comes after the firm appointed Jean-Luc Butel as its new corporate vice-president and president of international operations earlier this month.